AI model finds the cancer clues at lightning speed
Say goodbye to hours, even days, of detective work
Glycans, or structures of sugar molecules in our cells, can be measured by mass spectrometry. One important use is that the structures can indicate different forms of cancer in the cells.
However, the data from the mass spectrometer measurement must be carefully analysed by humans to work out the structure from the glycan fragmentation. This process can take anywhere from hours to days for each sample and can only be carried out with high confidence by a small number of experts in the world, as it is essentially detective work learnt over many years.
Automating the detective work
The process is thus a bottleneck in the use of glycan analyses, for example for cancer detection, when there are many samples to be analysed.
Researchers at the University of Gothenburg have developed an AI model to automate this detective work. The AI model, named Candycrunch, solves the task in just a few seconds per test. The results are reported in a scientific article in the journal Nature Methods.
The AI model was trained using a database of over 500 000 examples of different fragmentations and associated structures of sugar molecules.
“The training has enabled Candycrunch to calculate the exact sugar structure in a sample in 90 per cent of cases,” says Daniel Bojar, Associate Senior Lecturer in Bioinformatics at the University of Gothenburg.
Can find new biomarkers
This means that the AI model could soon reach the same levels of accuracy as the sequencing of other biological sequences, such as DNA, RNA or proteins.
Because the AI model is so fast and accurate in its answers, it can accelerate the discovery of glycan-based biomarkers for both diagnosis and prognosis of the cancer.
“We believe that glycan analyses will become a bigger part of biological and clinical research now that we have automated the biggest bottleneck,” says Daniel Bojar.
The AI model Candycrunch is also able to identify structures that are often missed by human analyses due to their low concentrations. The model can therefore help researchers to find new glycan-based biomarkers.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!